Gilead Wins U.S. Approval for First HIV Prevention Pill
This article is for subscribers only.
Gilead Sciences Inc. won U.S. approval to market its HIV treatment Truvada to prevent the virus that causes AIDS in healthy people who are at high-risk of contracting the disease.
The daily drug is the first aimed at reducing the risk of HIV in uninfected people as part of a strategy that includes other prevention methods such as safe sex practices, risk reduction counseling and regular HIV testing, the Food and Drug Administration said today in a statement. Truvada will carry a boxed warning to physicians and patients that the drug should only be used by those confirmed HIV-negative prior to prescribing the drug and at least every three months during use.